Aurora Improves Offerings in Australia with New Range of Premium Dried Flower Products
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is pleased to announce the expansion of its portfolio with the introduction of a new range of premium dried cannabis flower products. Now available for doctors to prescribe to patients in Australia, the new products developed by Aurora and manufactured at its EU-GMP and TGA-GMP certified facility, will be distributed by MedReleaf Australia, a premier distributor of medical cannabis products holding the second position in the Australian market.
The new dried flowers, including Black Jelly, Chemango Kush, and Moon Berry, are proprietary cultivars cultivated exclusively by Aurora. Vespera, a previously existing proprietary cultivar, is also set for relaunch under the Aurora brand. These products mark a significant step forward for MedReleaf Australia as they continue to expand their offerings under the Aurora brand. The dried flower products are available now in four 10g formats including:
Aurora Moon Berry T9/C13 Balanced
Aurora Black Jelly T28/C1 Sativa
Aurora Chemango Kush T29/C1 Indica
Aurora Vespera T1/C17 CBD
“This expanded offering aims to serve patients with more choice, novel cultivars and expertly grown product,” said Kristin Viccars, Managing Director at MedReleaf Australia. “With the launch of the new Aurora dried flower products, MedReleaf Australia reaffirms its commitment to providing high-quality medical cannabis solutions that meet the diverse needs of patients across Australia.”
The expanded range of Aurora products caters to the market demand for more affordable options without compromising on quality. With a focus on sustainability, the 2.0 genetics employed in these cultivars ensure reliable large-scale cultivation to meet market demand while maintaining elevated quality standards.
Furthermore, the MedReleaf Australia family of brands now focuses on three core brands – CraftPlant, offering a hand-crafted, premium range of products; Aurora, for innovative and affordable options; and IndiMed, providing a company-funded concession range.
For additional information doctors and health care professionals can contact MedReleaf Australia’s clinical support team or visit their website: www.medreleafaustralia.com.au.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company’s adult- use brand portfolio includes Aurora Drift, San Rafael ’71, Daily Special, Tasty’s, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America’s leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora’s Common Shares trade on the NASDAQ and TSX under the symbol “ACB”.
About MedReleaf Australia:
MedReleaf Australia is a subsidiary company of Aurora Cannabis Inc., established in 2016 and acquired in 2024. MedReleaf is licensed by the Australian Federal Government’s Office of Drug Control (ODC) to cultivate and manufacture medical cannabis. MedReleaf also has licenses to import, export and wholesale medical cannabis. Its wholly owned subsidiary in New Zealand also has a Medicinal Cannabis Supply Licence issued by the New Zealand Ministry of Health. MedReleaf Australia is backed by more than 50 combined years of pharmaceutical and healthcare expertise, is driven by Research and Development, and has an exclusive strategic partnership with Canada’s Aurora Cannabis Enterprises. An asset-lean distinct business positioned to take advantage of a rapidly growing market, built to service the Australian and New Zealand medical industries including doctors, pharmacists, and patients.
Forward Looking Information
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the continued expansion of the Company’s productportfolio in Australia, including through the introduction of a new range of dried cannabis flower products and the relaunch of Vespera; and the Company’s continued commitment to the Australian medical market.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management’s estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management’s estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information from dated June 14, 2023 (the “AIF”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC’s website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-improves-offerings-in-australia-with-new-range-of-premium-dried-flower-products-302131189.html
SOURCE Aurora Cannabis Inc.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
